Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
April 29, 2021
Earnings Call Speaker Segments
Jake Elguicze
executiveHello, everyone, and thanks for joining us on the Teleflex, Inc. First Quarter 2021 Earnings Conference Call this morning. You can find the press release and the slides that go with this call on our website, www.teleflex.com. Just a note that this call is being made available on our site, and a replay can be accessed by calling (800) 585 to 8367, or if you're calling internationally, (416) 621 to 4642, with passcode 6194708. On the line with us today are Liam Kelly, Chairman, President and Chief Executive Officer, along with Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom are going to give prepared remarks, and after that, we'll open things up for Q&A. Before we get started, I want to remind everyone that certain matters we'll discuss on this conference call will include forward-looking statements about future events, as described in our slides. Please be aware that these statements are forward-looking in nature and involve risks and uncertainties, and actual events or results could differ materially. The factors that might cause actual results or events to differ materially include, but aren't limited to, those referenced in today's press release and in our filings with the SEC, including our Form 10-K, which you can access on our website. During this conference call, you'll hear management discuss intra-quarter business performance. Management is offering this commentary to give the investment community additional insights into trends, and these disclosures might not occur in later quarters. With that, I'd like to hand the call over to Liam.
Liam Kelly
executiveThanks, Jake, and good morning to all of you; it's great to be here with you today. Our performance in the first quarter has us very pleased, coming in above the guidance we gave the investment community during our Q4 call in February, and showing better underlying revenue trends in the product categories hit hardest by delayed deferrable procedures — particularly Interventional Urology, Interventional Access and Surgical. Revenue for quarter 1 came in at $633.9 million, a decline of 2.6% versus the same period a year ago on a constant currency basis, as COVID-19 headwinds persisted. If we adjust for the two fewer selling days in the first quarter of 2021 relative to the first quarter of 2020, constant currency growth for quarter 1 was slightly positive, at roughly 0.1%, representing the third quarter in a row of improving growth rates and the first return to days adjusted constant currency growth since COVID began in the second quarter of 2020. On the earnings per share side, our adjusted EPS of $2.87 likewise came in well above what we told The Street to expect. That reflects the procedure recovery we observed on a monthly basis as the quarter progressed, along with disciplined management of operating expenses. Finally, in the first quarter of 2021, we made a commitment to a fresh restructuring plan aimed at streamlining a number of business functions. Here at Teleflex, continuous improvement matters to us, and we keep pursuing new opportunities to make our business more efficient and cost effective. Now let me walk through our first quarter results in more detail. As I noted, quarter 1 revenue fell 2.6% on a constant currency basis. The revenue decrease stemmed mainly from ongoing COVID-19 headwinds plus the effect of two fewer selling days this quarter versus the prior year period. After accounting for the number of selling days, contributions to day sales adjusted came in positive from Vascular, Anesthesia, Surgical and Interventional Urology; those gains were countered by decreases in Interventional OEM along with our Other segment. Turning to margins, adjusted gross margin reached 59.4% while adjusted operating margin was 27.5%. Compared with a year earlier, that represents an increase of 210 basis points for gross margin and 190 basis points for operating margin; our growth and operating margin results left us encouraged, since they demonstrated that the business is capable of producing meaningful leverage despite persistent COVID headwinds that continued to pressure revenue. We've actually been showing a lot of operating leverage across the income statement — in fact, our adjusted gross margin and adjusted operating margin were the best they've been since we turned into a pure-play medical device company. For the first quarter, adjusted EPS came in at $2.87, which is up 5.5% compared to the same period last year and well above what we told The Street to expect back on our quarter 4 call. Overall, I couldn't be happier with how we performed financially in quarter 1 — it demonstrates how resilient our diversified global product portfolio is, and it also shows we're making headway on the margin goals we've set for the longer term. With that said, let's dig into the revenue results a bit more. Let me begin with the revenue breakdown for our reportable segments. Unless I say otherwise, any growth rate I mention will be calculated on a constant currency basis. During the first quarter, the Americas generated $375.5 million in revenues, which represents growth of 4.7%, or 8.3% once you adjust for selling days. On a days adjusted basis, the growth this quarter was driven by strength in Vascular, Anesthesia, Surgical and Interventional Urology. EMEA recorded revenues of $141.2 million, down 16.9%, or 14.4% on a days adjusted basis. On the EMEA side, we were up against a difficult comparison from the same period last year, which had featured a surge of orders placed before the first wave of COVID, and on top of that, Q1 2021 brought heavier COVID restrictions and more postponed elective procedures. Turning to Asia: revenue reached $63.7 million, up 10.3%, and selling days had no effect there. The key point is that China bounced back with strong double-digit improvement, while India and Korea also posted double-digit gains, which was more than enough to counterbalance pullbacks in Japan and Australia. The Americas and Asia are, as expected, bouncing back faster than Europe. To wrap up, revenue from our OEM segment came in at $53.5 million. That figure is down 17.1% in constant currency terms, or 16.3% once you adjust for selling days. We expected this — the COVID recovery is still hitting our OEM business with a delayed effect. Those who follow Teleflex know that this segment provides complex catheters and surgical sutures to device makers, and what happened in the first quarter comes down to fewer orders from those customers, since their business depends on nonemergent procedures. Turning to the HPC purchase: we're glad the integration work is behind us, and extra capacity will be arriving during the coming two months, which ought to support second-half growth. Now let's talk about sales broken out by worldwide product category. Just like what I said earlier about our reportable segments, anything I say about growth in these categories is also given on a constant currency basis, and I'll add detail on selling day adjustments too. Beginning with Vascular Access: Q1 revenue rose 5.8%, reaching $164 million, or 9.3% once selling days are adjusted for, thanks to robust results from central venous catheters, EZ-IO and PICC product lines. Next, Interventional Access. Q1 brought in $96.2 million, down 6.4% from a year earlier. Once you account for selling days, the drop was 3.8% year over year. Most of that decline traces back to nonemergent procedures recovering more slowly because of COVID. Partially making up for it was MANTA large-bore closure revenue, up roughly 30% worldwide on a selling-day-adjusted basis. Now on to Anesthesia. We posted $84.9 million in quarter 1 revenue, reflecting 7% growth, or 9.9% when adjusted for selling days. The lift came from Z-Medica, which delivered a strong result that exceeded our expectations, while softer demand for laryngeal masks and regional anesthesia products worked partly against that. Moving on to Surgical. We posted $80.4 million in revenue, up 2.3%, or 4.7% once selling days are adjusted for, powered by our polymer ligation clips and instruments, with chest drainage and metal ligation declines providing a partial offset. Turning now to Interventional Urology. First quarter revenue reached $73.4 million, a 1.3% decrease. On a selling-day-adjusted basis, UroLift grew roughly 1.9%. Throughout the quarter, canceled procedures kept dragging on growth as COVID case counts spiked during January and February; even so, as the quarter wore on, we felt very encouraged by the robust double-digit growth seen in March. The strong momentum UroLift experienced in March carried into April, with our average daily sales trends continuing to improve. Notably, April's average daily sales returned to pre-COVID daily rates on a consistent basis for the very first time. We still see UroLift as among the earliest procedures to be done as conditions begin improving once more.
Liam Kelly
executiveAdditionally, during the first quarter, we educated 115 new urologists, and we are firmly on course to meet our yearly goal of preparing somewhere between 450 and 500 new urologists over the course of 2021. And last, our Other segment — made up of our respiratory and urology care products — saw a decrease of 15.3%, or 12.6% when adjusted for selling days, amounting to $81.7 million. This drop mirrors challenges affecting elective procedures, along with tough comparisons against the previous year tied to COVID-related ordering in EMEA. That wraps up what I have to say about our revenue results for quarter 1. Now moving to a few clinical and commercial developments. I'd like to give you an update on what we're doing with direct-to-consumer for UroLift. Building on a strong 2020 effort, in which we doubled awareness of UroLift among the targeted group of men living with BPH, and consistent with our plan, we've chosen to boost our investment for 2021 and conduct a national campaign spanning the entire year. With this year's effort, we're refining our network choices, updating the creative, and coordinating with social media initiatives to boost the total effect. We still see DTC as a multiyear catalyst for UroLift within the United States, since we remain in the early stages of market adoption and patient awareness. In fact, UroLift is setting the pace in BPH, and this marks the first occasion in recent years that a BPH brand has connected with patients directly in a significant manner. Now on to UroLift 2. We keep making headway with our controlled launch, and we are still on schedule for a broader rollout starting in the second half of 2021. We stay confident that shifts toward UroLift 2 will keep happening over time, and we still anticipate delivering meaningful margin expansion once the revenue base has fully transitioned. When it comes to the UroLift ATC device, the launch keeps going quite well. We've held several case days, and urologists consider the device intuitive to use, and they appear to value that it simplifies carrying out procedures involving obstructive median lobes. As for Japan, we are still on course for a reimbursement decision in 2021, and we see the roughly $2 billion addressable market as an additional growth driver that should serve as a favorable catalyst for the foreseeable future. We also keep working toward commercialization in France. We expect to carry out our first cases in the second quarter. With numerous catalysts lined up across key geographies, such as the U.S. and Japan, we stay confident that UroLift will grow into a strong global franchise, tapping into a sizable multibillion-dollar opportunity. Finally, before I hand the call to Tom, I want to share clinical updates covering two recently published studies from our Interventional Access business unit. The MARVEL real-world study came out recently in December of 2020. It followed 500 patients at 10 centers around the world who had undergone transfemoral large bore percutaneous procedures. For the primary endpoints, time to hemostasis had a median of 50 seconds. The main vascular complication rate tied to the MANTA access site matched what we saw in the safe MANTA IDE pivotal trial for its primary endpoint. According to the study's conclusion, MANTA proved to be both safe and effective for closing large bore access in real-world settings. Beyond the registry study I just mentioned, a separate meta-analysis came out in February of 2021. That pooled analysis looks at data from almost 900 patients, taken from the CE mark and SAFE pivotal trial plus the MARVEL registry study. Among the key findings were a high rate of technical success, quick hemostasis, and few complications; median time to hemostasis in this study came in at 31 seconds. On the whole, we keep putting money into clinical and commercial catalysts that should support our upper single-digit revenue growth goals for this strategic business unit once conditions normalize. That wraps up my prepared remarks. At this point I'd like to hand the call over to Tom so he can walk through our first quarter financial results in more detail. Tom?
Thomas Powell
executiveThank you, Liam, and good morning to all of you. Now that we've covered the company's revenue results, I'll start with the gross profit line. Adjusted gross margin for the quarter came in at 59.4%, which is the best level since Teleflex turned into a pure-play metal device company, and that marks a 210 basis point gain over the same period last year. Product mix, along with benefits from M&A and restructuring, largely drove this gross margin improvement, though foreign exchange headwinds offset part of it. Similarly, adjusted operating margin for Q1 hit 27.5%, which is likewise the strongest it has been since Teleflex turned into a pure-play metal device company, and that represents an increase of 190 basis points versus the same period last year. The improvement was driven primarily by the gross margin gain, though a normalization of compensation expense accruals partly counteracted it. Moving further along the P&L, net interest expense totaled $16.1 million for the quarter, up slightly from $14.9 million a year earlier, due to higher average debt outstanding. Following the close of the quarter, a notice of redemption was sent to holders of our outstanding $400 million aggregate principal amount of 4 and 7/8% senior notes due in 2026. That redemption is going to be paid for through funds drawn on our revolving credit facility. Let's move to taxes now. We posted an adjusted tax rate of 13.9% for the first quarter, up 140 basis points versus the same period a year ago. The main driver of this year-over-year rise in our adjusted tax rate is a reduced benefit from stock-based compensation compared with what we had in the prior year period. Looking at the bottom line, adjusted earnings per share for the first quarter increased 5.5% to $2.87. An estimated favorable foreign exchange impact of about $0.13 is baked into that figure. I want to highlight one more restructuring program that we recently made public. During Q1 2021, we launched a restructuring effort designed to make several parts of our operations more efficient. We figure the total pretax restructuring costs will land somewhere from $7 million to $9 million, largely severance payments, along with an additional $3 million to $4 million tied to the restructuring itself. Savings from this plan ought to begin showing up during 2021, and once everything is fully in place, we anticipate yearly pretax savings ranging from $13 million to $16 million. Taking stock of every restructuring and cost-cutting initiative we currently have underway, the combined pretax savings still to come from all active programs should fall in the range of $53 million to $67 million. You can find more specifics on these programs in the appendix of the earnings presentation. About 50% of the savings that are left ought to be achieved across 2021 and 2022, and most of it should be captured by 2024. That gives us solid visibility into margin growth that doesn't rely on revenue for as far out as we can see. Now turning to a few balance sheet and cash flow items. In Q1 of 2021, operations generated $110.8 million in cash, versus $11.5 million of net cash used during the same period a year earlier — a $122.3 million improvement year over year. The increase relative to last year resulted from lower contingent consideration payments, smaller payroll and benefit-related outflows, and stronger collections on accounts receivable. On the whole, our balance sheet remains healthy. At the end of Q1, we had $324.6 million in cash. We reduced our debt by $100 million during the quarter, and our net leverage finished the period at about 2.9 times. Once the quarter was over, we paid back an additional $25 million on our revolver. Moving on to guidance, starting with our 2021 revenue outlook. We now anticipate constant currency revenue growth between 8.5% and 9.75% compared to 2020. This is an increase from our original guidance, which projected constant currency revenue growth of 8% to 9.5%. The updated outlook speaks to how much faith we have in the company — including, for instance, the Q1 performance, which landed ahead of what we had projected. We see our offerings in Interventional Urology, Interventional Surgical and Anesthesia driving a meaningful share of our constant currency revenue expansion across 2021. On top of that, we continue to anticipate growth of no less than 30% in our Interventional Urology business compared with 2020 levels. When it comes to the midpoint of our constant currency guidance range, we've baked in roughly a 2.5% lift from buying Z-Medica. Turning to currency: we still believe foreign exchange rates will add about 2% as a tailwind to revenue growth. As a result, we now look for as-reported revenue to rise somewhere between 10.5% and 11.75% versus 2020. In dollar terms, that works out to somewhere from $2.804 billion to $2.835 billion. Now let's look at gross margin. For 2021, our updated expectation is that adjusted gross margin will climb by 155 to 255 basis points, landing in a range of 58.25 to 59.25, which is 25 basis points better than what we previously projected. The main force behind this margin growth should be a better product mix tilted toward higher-margin offerings such as Interventional Urology, Interventional Access and Surgical. We're also seeing gains from initiatives to boost manufacturing productivity, from footprint restructuring programs we announced earlier, and from buying Z-Medica. Inflation is likely to take away somewhat from the year-over-year improvement in gross margins. Now on to adjusted operating margin. Our outlook still calls for adjusted operating margin to rise somewhere between 110 and 210 basis points, landing in the 26% to 27% range. Most of that improvement should flow through from gross margin, though it will be partly offset as spending returns to more typical levels on things like management compensation, commissions, targeted headcount additions, and the possibility of additional strategic investments in support of key growth drivers such as UroLift and MANTA. Moving further down the P&L. Interest expense is now projected to come in somewhere between $61 million and $63 million. That's against our original guidance, which had interest expense landing between $63 million and $65 million. Lower interest costs mostly stem from us paying down debt quicker than we had originally planned, along with LIBOR coming in under what we expected. We had already baked the early retirement of the 2026 notes into our full-year interest expense assumptions. Turning to taxes, we now expect our adjusted rate to come in at 13% to 13.5%, a 50 basis point improvement versus our prior guidance. Given all of that, we're pleased to raise our adjusted EPS outlook to $12.65 to $12.85, which implies growth of 18.6% to 20.4%. And finally, though giving quarterly financial guidance isn't something we typically do, with the COVID situation still unfolding, I'd like to offer some detail about what we anticipate happening in Q2 of this year. If we look at the midpoint of our updated guidance ranges, for the second quarter of 2021, we anticipate delivering roughly 24.5% of our reported revenue for the full year and about 22.5% of our adjusted earnings per share for the full year. This outlook assumes that COVID will keep creating disruption through the first half of the year. That wraps up my prepared remarks. I'd like to hand the call back over to Liam for some closing commentary. Liam?
Liam Kelly
executiveThanks, Tom. To wrap up, I want to emphasize our key — the three main points from this quarter. To start, we had a solid first quarter, with results on both the top and bottom lines exceeding what we had anticipated. Next, we unveiled an additional restructuring initiative, which shows the work our organization is doing to keep improving continuously. This move also adds to our confidence in the efforts to expand margins over the long term. And last, we lifted our guidance for revenue and adjusted earnings per share, which mirrors a robust quarter 1 along with our view for the rest of the year. I'd like to end by expressing gratitude to the whole Teleflex team worldwide, who have put in tireless effort throughout the pandemic. As we start to emerge on the other side of COVID, we'll keep honoring our commitments to our patients, clinicians, communities and, naturally, our shareholders. That wraps up my prepared remarks. At this point, I'd like to hand the call back to the operator for Q&A.
Richard Newitter
analystThanks for the detail regarding what's happening with UroLift trends. Perhaps to begin there; you said growth for UroLift, or Interventional Urology, has come back to where it stood before COVID. I'm just wondering, is that — during the first half of 2020 you saw differing rates, 40%, which then climbed to 50%, while in Q1 of 2020 it was roughly 20%. For the early trends you're pointing to here in 2Q, which of those trajectories ought we to treat as the benchmark?
Liam Kelly
executiveYes, Rich, many thanks for asking. So the trends we're citing are from 2020 before COVID; when adjusted for days in Q1 2020, despite COVID's effect during the final days of — or the final week of March, we posted growth of around 26-plus percent versus the prior year. So the trends observed during April leave us quite encouraged. At various points amid COVID's impact, as we reached November of last year, Rich, we did witness days when average daily sales returned to a pre-COVID level. Yet consistency, where that holds across a sequential run of weeks, eluded us until April, and that is extremely, extremely encouraging for us; and I'll add — another figure, I believe, merits consideration is that when you set UroLift growth in this Q1 of 2021 against Q1 of 2019, it comes to roughly 30%. So we're quite pleased that we can reaffirm our expectation for the entire year for UroLift, growth of plus 30%, and what we've observed during the last few weeks of March, but even more significantly, during the opening weeks of April, has given us confidence that we will certainly manage to reaffirm that long-term — or that full year guidance.
Richard Newitter
analystAppreciate the additional detail. I have a couple of quick follow-ups regarding UroLift. First, I'm aware there have been some shifts in management within the organization — the Head of — the President of UroLift, in line with what you'd previously indicated and consistent with the expected timeline, stepped down when the year came to a close. Could you elaborate on that a bit? I think it would ultimately be helpful to know whether anything might be shifting in how you see the market, the direct-to-consumer efforts, or management transitions that could be affecting the business? Or is it simply COVID that caused the still slow performance during the first quarter?
Liam Kelly
executiveYes. So I wouldn't describe the first-quarter performance as slow. Keep in mind that during January and February, COVID was considerably worse than it had been in the fourth quarter. And for us to achieve roughly 2% growth in Q1 compared — in line with Q4, I'd view that as something we accomplished. One more piece of context I'd offer, Rich: during the first two months, January and February, UroLift saw a decrease of about minus 8%; then in March, we had positive absolute year-over-year growth exceeding 30% for that month. And as I mentioned before, we kept seeing that improving trajectory as we moved into April. So our feelings about UroLift are really positive. Nothing has shifted in the end markets, and we remain quite optimistic. As expected, the President of the business units did depart when the year ended, but an industry veteran is joining us to lead that business unit, and the core team remains intact. Our turnover in that business unit is considerably lower than our turnover anywhere else at Teleflex; and Teleflex's turnover sits well below industry averages. I've said this often, Rich — you simply can't beat culture, and our people stay at Teleflex because of the culture and because of the substantial opportunities available there. So there are no significant changes within the organization below the President level.
Richard Newitter
analystThank you very much, I really appreciate that.
Cecilia Furlong
analystExcellent. Thanks for taking our questions. I wanted to stay on the topic of UroLift. You mentioned expansion outside the United States, specifically into France, plus Japan launching during the second half of this year. As we consider both guidance and how we recover from COVID, could you share what you anticipate from the U.S. market bouncing back due to the DTC campaign as it moves into OUS? And building on top of that, when you consider how UL2's rollout affects gross margin, I'd really like to hear your perspective on what the pacing will look like across the year?
Liam Kelly
executiveOkay. So once more, we have restated our more than 30% expansion for UroLift during this 12-month period; and when it comes to increases in France and Japan, we view those as additive to the typical growth rates we have for UroLift; we believe the expansion and rebound for our UroLift will truly be a U.S. event in 2021, and our suggestion to the investment community is to concentrate on the American market; we will bring in a certain amount of revenue in Japan, but a registration study is required of us that we must finish and from which we must collect data. From my perspective, the launches in Japan and France really belong to the 2022 story, and that's when you'll see the extra revenue truly start to gain traction. As I said earlier, I see this as an additional growth driver moving forward. Regarding UL2, we still expect to have essentially completed the transition of the key North American market by the end of 2022, and our gross margins should improve by 4 percentage points, which works out to about 40 basis points for Teleflex as a whole. As for DTC, what we saw last year with our DTC campaign leaves us feeling pretty optimistic. As I mentioned in my prepared remarks, we intend to keep the DTC campaign running for a full twelve months. Based on what we learned during that time, we're putting in twice as much money, but the impressions we anticipate delivering will grow by over two times—so for 2021 compared with 2020, we expect roughly 125%-plus additional impressions from this campaign. We're also very encouraged by the level of patient engagement with the urologist, and by the appointment volumes we're seeing come out of that. We're boosting our investment in direct-to-consumer efforts, which means running that campaign across all of 2021 rather than just part of 2020. And with COVID conditions improving, plenty of patients we connected to a urologist thanks to that DTC push ought to convert into procedures, since folks are gaining confidence about coming in and having those procedures performed during the latter portion of 2021.
Cecilia Furlong
analystGreat. And I suppose I was just hoping to check in on Z-Medica — you mentioned how Q1 went, a touch better than what you'd been expecting. Could you share a bit about the way that integration work has been progressing up to now? And also, genuinely, what's your thinking on that first $60 million to $70 million figure you flagged when the acquisition was announced?
Liam Kelly
executiveThank you. Yes; the integration, then, is going remarkably smoothly. Everyone at Z-Medica is very much welcomed into the Teleflex family. We're not seeing any turnover among the retention pool we identified. There are roughly 21 work streams tied to the integration, and we've already gotten about 35% of the way through. As for the $60 million to $70 million and the $0.21 to $0.26 earnings guide we provided, we believe we're sitting quite comfortably inside that $60 million to $70 million, and right from the start the product has been performing beyond what we'd have expected. So we're genuinely pleased with the way Z-Medica is going.
Matt Taylor
analystI wanted to return to UroLift and ask about new versus existing surgeons. Can you share any insights on the trends you're observing there? Are surgeons who've previously performed UroLift still demonstrating same-store growth? Or what portion of new growth originates from each of those categories?
Liam Kelly
executiveHistorically, roughly 2/3 of our growth has come from existing users, while 1/3 has come from new ones. We haven't observed any meaningful shift in that split. When we reached the fourth quarter and discontinued within the first, the average number of procedures performed by urologists has remained quite stable, which is very encouraging. Something we did notice in the first quarter and throughout COVID was a percentage shift away from the hospital toward the ASC and the office during COVID, and we saw a swing of a few percentage points. We've actually seen some of that shift return to the hospital as patients now feel more confident about going back to the hospital and having their cases done. So we're quite encouraged by this, because our procedure is performed across all sites of service. It's done in the hospital, the ASC, and the office. And as we observe all of those sites of service starting to recover, as we did in the first few weeks of April, the trends are truly encouraging for UroLift, Matt.
Matt Taylor
analystAll right, that's excellent. And clearly, that April figure is quite encouraging. But here's what I'm wondering — is your assumption that these same levels will carry on throughout the quarter? Or might we actually witness a bit of an acceleration in momentum? In other words, are your customers or your sales team signaling that a pipeline exists from those Q2 canceled procedures, and that it's set to recover as vaccination rates climb?
Liam Kelly
executiveMatt, we certainly have visibility into what got canceled during Q1, and we also know the Q2 picture; what we've done is take 2019's baseline cancellations and layer in the data we have on the extra ones. Now — Q1 cancellations ran above Q4, which is what you'd anticipate given that COVID was hitting harder, and we saw record peaks specifically in January and February. In Q4 we had 850 cases, translating to roughly $4 million, while Q1 came in at just under 920; that means beyond the base rates, over $4 million in procedures were called off. At some point, you'd expect those postponed procedures to return as patients gain more confidence and choose to go ahead with them. So regarding UroLift, our outlook right now is very positive. And naturally, as mentioned before, additional growth catalysts arrive later in the year and into 2022 — Japan, France, and additional markets among them.
Larry Keusch
analystLiam, I was just hoping we could establish a baseline regarding Japan. Perhaps you could — I definitely picked up on the message that — there's this post-market study you were required to complete, and you aren't anticipating much revenue during this year. Still, I'm just attempting to work through what occurs with approval for the UL 2 and then, in sequence, what occurs regarding reimbursement; could you maybe just guide us through your thought process on the timing there?
Liam Kelly
executiveSure, Larry; so here's where we stand — every piece of documentation has been readied and turned in to the regulators. And — my apologies, we will have those ready in time for the June meeting, though whether they'll actually examine them at that June meeting is unknown to us. However, should they fail to review and issue a ruling in June, a decision will come in December or — excuse me, in September; that's the crucial milestone, Larry, determining when a reimbursement ruling arrives for Japan. The moment that ruling comes through, we'll start performing procedures, fulfilling the PMDA mandated study we're obligated to carry out. Our team is already in place there. Market development specialists are already on the ground. We've already started hiring extra sales staff locally, expecting that reimbursement decision to come. And Japan offers one benefit compared to what we faced in the United States in that it operates as a single-payer market; therefore, once reimbursement is granted, we'll have coverage at every site throughout all of Japan. And I believe at that point we'd witness revenue in Japan scaling up as 2020 progresses and afterward. And once more, to repeat my earlier point, we view this as adding to the normalized growth levels of UroLift on top of what we've observed chiefly in the United States.
Larry Keusch
analystAll right. There's something I'd like to ask Tom, though first let me make sure I understand one point, Liam. So you're telling us the regulatory clearance filing hasn't been submitted at this stage? And that step needs to be finished prior to the reimbursement meeting? Or is that the way it works?
Liam Kelly
executiveSorry. No, Larry, regulatory clearance is something we already hold, my apologies. What I was referring to was the reimbursement submission.
Larry Keusch
analystI suppose this one is for Tom. Obviously, when it comes to gross margin, Tom, you're getting close to the sorts of goals you set out in the pre-COVID LRP. Once more, I just wanted to consider, or perhaps have you speak a bit to how you view whether the gross margin can be sustained following what we observed during the first quarter? And then, as a follow-up to that, regarding restructuring, again, you pointed to the pretax savings sitting ahead of you across the coming several years. Should we view those as essentially all flowing down to the bottom line? Or might you actually put some of those restructuring savings to work in order to fuel growth?
Thomas Powell
executiveWell, let me begin with whether the gross margin can be sustained. As we've discussed before, two factors really propel our gross margin — chiefly mix, and I'd say UroLift is the biggest driver, plus we now have Z-Medica added this year. So if UroLift and our other high-margin product offerings keep growing faster than the rest of the business, we will keep seeing margin expansion for this year and going forward. Now, as for the other element, the restructuring programs, as I mentioned, we already have a couple of years of programs laid out that exist, and we anticipate capturing some substantial savings. If you run the numbers on that, it comes to roughly one basis point of margin expansion right there. When we consider whether we drop this through, from where we sit, we're going to keep assessing what options exist to examine chances to boost growth through additional investment behind our high-margin brands like UroLift, Z-Medica, MANTA, along with weighing what amount of profitability increase we have. So we have the chance to keep generating meaningful top line growth, meaningful margin expansion, and that will convert into meaningful earnings per share growth. And we'll keep assessing what opportunities exist to invest further so we can accelerate that top line even more.
Matthew Mishan
analystTom, let's return to gross margin for a second. I get that mix is the main force behind much of this gain, but looking quarter by quarter, Z-Medica and UroLift are both climbing, sales are climbing, and presumably the share of COVID-related products is easing somewhat. So why should gross margins fall from this point across 2Q, 3Q and 4Q while sales keep rising? And what is cancelling that out?
Liam Kelly
executiveFirst off, I'd note that during the first quarter, our manufacturing had an exceptionally clean stretch when it came to corona. And beyond that, picking up on what you just said, when we think about how the second half of the year recovers, we — what I mean is, during the first quarter, EMEA and OEM each saw revenue fall roughly 70% on a constant currency basis. Looking ahead to the second half, we anticipate those two businesses turning positive, and that shift will hurt our mix. That in turn will eat into part of the stronger growth coming from UroLift and our other high-margin brands. Of course, we're still watching to see exactly how the recovery unfolds across the coming weeks and months; and ideally, as the year progresses, we keep seeing favorable movement on the gross margin line.
Matthew Mishan
analystAll right, that's great. And regarding the OEM business, at what point does that stock level return to normal relative to production — I mean relative to what customers are actually doing?
Liam Kelly
executiveMatt, the lag on that ought to be roughly one quarter. What that means is you ought to see improvement starting in quarter two. And once you're in the back half of the year, it should really begin gaining momentum; so the delay works out to roughly one quarter. My sense, then, is that Q2 OEM numbers would come in above what they plainly were this quarter, and after that you move into positive countries as you reach the back half of the year. For the year in total, OEM ought to expand at a rate in the mid single digits.
Matthew Mishan
analystAll right. Great. And turning back to Tom: so free cash flow came in really strong during Q1. What's the right way for us to frame free cash flow for 2021? And are we at the stage now where that inflection point you mentioned for 2020 and 2022 is actually showing up?
Thomas Powell
executiveYeah. My view on free cash flow is this: we'd anticipate growth roughly matching earnings growth, somewhere around 20%. There are a few dynamics at play in 2021. To start with, net income should rise. We'll also get a lift from lower contingent consideration payments. Last year we paid out just shy of $18 million, and this year we anticipate that figure dropping meaningfully. That said, during last year we ended things with an exceptionally robust collection cycle, with DSOs falling well below what we typically see historically; and for this year, we've built the plan around getting nearer to that historical average — and if favorable collection trends persist, free cash flow growth could exceed the 20% figure I just mentioned.
Liam Kelly
executiveDrew here, filling in for Matt. I suspect I already know what you'll say, but I'd like to ask about how the competition looks for UroLift. Yesterday Boston talked up solid momentum with its Rezum offering. And I believe Olympus is also bringing a new product into this space. Is there anything fresh on those technologies? Also, are you noticing any movement in terms of utilization across the market? So nothing has shifted in the marketplace, from what we can see. Honestly, calling year-over-year growth in conditions like these is difficult, since you can't know what the comparable period looked like for some of these companies. What I can share is that during the last quarter, across Teleflex as a whole, we posted 5.5% growth on a days-adjusted basis. And if you examine how Teleflex as a whole performed in 2019, on a constant currency days-adjusted basis, our growth was 5.8% versus 2019. So in our view, the momentum is clearly trending in a favorable direction for us. On top of that, we observe nothing changing in the end markets. Ultimately, everything hinges on patient outcomes — no sexual dysfunction, whether the man will need a catheter, and revision rates for UroLift that stack up against the gold standards, which is a hard bar. And naturally, keep in mind that with UroLift the man gets to choose where the procedure is performed. Does he prefer a hospital, an ASC, or an office? With certain of these competing technologies, patients face limits on where the procedure can take place. So the end market hasn't changed, and I can state unequivocally that not a single customer has been lost to any competitor.
Andrew William
analystAlright, that's clearly wonderful to hear. And congratulations on the impressive results with MANTA. I think you said something about growth of 30%-plus. Could you perhaps give us some context on how that figure compared with the estimates, and then how it compared with the penetration goals you set out a couple of quarters back?
Liam Kelly
executiveWe're extremely happy with that growth. You're right, within the quarter it came in at 30% growth, which is really encouraging; it matches our trajectory, even with COVID getting worse in January and February; and we anticipate that momentum continuing to build throughout the rest of the year, and we do think we'll reach 8%-plus penetration by year-end. So MANTA is delivering right in line with what we expected, and it gives us a lot of encouragement.
Andrew William
analystThanks.
Anthony Petrone
analystPerhaps one about UroLift, plus a few questions on regions. First, on UroLift, maybe just the competitive situation, I suppose, against the other devices already out there — Boston Scientific mentioned Rezum somewhat during their call, and they too experienced rising volumes during March. So an update on how competition is shaping up and on adding new sites would be my first question; and then perhaps a quick second one about EMEA. Or maybe, Liam, you could speak a bit more generally about EMEA — clearly it trailed during the quarter. COVID remains somewhat elevated. Things are reopening there. So perhaps your thinking on when a turnaround will come about across EMEA? And after that I have one brief follow-up.
Liam Kelly
executiveRight, Anthony, thanks. So yes, the growth we recorded during March for UroLift came in above 30% — compared with the year before; so that has us genuinely upbeat; and we're also, as I mentioned previously, upbeat about the momentum heading into April, when our average daily sales kept improving sequentially into April, rising back above pre-COVID levels for the very first time. That represents a significant turning point for us, Anthony, as you can imagine. For a full year now, we haven't been consistently sitting back above pre-COVID levels; and so the team out there is truly energized about pushing that forward. As for what you asked about EMEA, EMEA came in as anticipated. Several things are at play there. During the same quarter a year ago, EMEA had booked a favorable $8 million COVID order. So they faced that difficult comparison. And as everyone is aware, vaccine distribution across Europe isn't progressing as effectively as it is in the United States. And I believe the rise in COVID cases throughout January and February and much of March in Europe was quite significant, with plenty of lockdown measures still in place. That said, April in EMEA has likewise been rather encouraging; so my expectation is that EMEA's second quarter will be far better than its first quarter; and I would be failing in my duty not to bring up APAC. APAC, Anthony, expanded by more than 10% on a days-adjusted basis during the quarter, up from minus 7% in quarter 4. So that represented an enormous turnaround for us, and China delivered a truly, truly robust first quarter as we observe procedures starting to return in that crucial geography for us. So that's a bit of regional detail, Anthony, regarding EMEA, and APAC as well.
Anthony Petrone
analystThat's really useful. I was hoping I might slip in a question about EZPlaz — perhaps a brief status update and a review of what's possible there, beginning with the military side? And more generally, as you bring it to market, ought we continue to view it as targeting a $100 million TAM.
Liam Kelly
executiveThat's right, you've got it exactly; EZPlaz does target a $100 million TAM — $25 million of that in the military and $75 million in the civilian segment. As everyone knows, we'll start in the military segment in order to help develop this product. The signs coming from the FDA have been quite encouraging. After we submitted our BLA, we received a letter from the FDA saying the application was complete enough for substantive review to get underway, and the BLA received a priority review classification, which tells us that it's on a fast track BLA. Extremely collaborative. Questions are coming back to us, which is exactly what we'd anticipate. Our team is responding to them. So it's been very collaborative going back and forth, and we'd expect approval on a normal timeline — pointing toward the fourth quarter. So as they work through this, we'll continue keeping the investment community informed.
Mike Matson
analystInvestors are clearly paying a lot of attention to the products you've bought, such as UroLift and MANTA. I sort of feel a bit bad for the people working on R&D over there. That said, I wanted to ask whether there are any new items developed in-house that have you excited and that we ought to know about?
Liam Kelly
executiveRegarding the members of our R&D team, they are accomplishing great things for us internally. We're excited about quite a few new offerings being created by our own people. In the anesthesia group, there's Polaris, a laryngoscope built around a handle plus blade setup, and it's picking up really solid momentum. Over in the Vascular business, Project Phoenix is a fresh ergo pack, and it's currently winning a great deal of traction for us in that group. In the Interventional group, we have the Wattson Guidewire, a 2-in-2 combination product set to launch later in the week, and we're highly optimistic about it. And naturally, AC3 keeps building terrific momentum, and we enjoyed a very strong quarter with that product, especially in China, as we begin rolling it out there now that approval has been secured. So all around the company, plenty of products are moving through the R&D group. And over the last several years, we've done quite well at lifting our revenue growth from new products into positive territory. A few years back, we used to produce 1% in new revenue growth from new products to the positive over the last number of years. A few years ago, we used to generate 2% in new revenue growth from new products, and we've moved that up to 1.5% to 2% over the past number of years. One more thing worth mentioning, though it isn't tied to your question about new products: we also saw positive pricing during the quarter. So I'd say we're quite encouraged by our capacity to raise prices even in this difficult climate, and that's another favorable indicator for us.
Mike Matson
analystAll right. I wasn’t trying to suggest they weren’t doing their jobs. It’s just that investors are paying attention to certain outside factors. So — and I wanted to give a — I was going to leave it to you to speak a bit about some of the inside factors. But and then, I suppose, only regarding MANTA; so MANTA, I mean — look, 30% growth. I don’t want to diminish that, that’s clearly very strong. But even so, I mean, the clinical data for this product is quite exceptional; so what resistance do you encounter? I mean is it only price? To me it just appears obvious to use this product; and if it is price, I mean, do any of the trials include any form of economic data? Or do you have any trials lined up to gather any form of economic data to sort of assist with the VAC committees and such?
Liam Kelly
executiveSo getting through the VAC getting through the VAC committees has not been a problem for us, Mike, with the MANTA product. During the first quarter, we’re really pleased with the 30%. What we struggle with is COVID in the first quarter, honestly, in terms of gaining access because it’s hard to gain access to the hospitals, particularly in January and February. Now I realize we’re sitting here in April, and we’re — January and February feel like a long time ago; but remember we were seeing 250,000 cases a day in January and February, they were far worse than November and December. So it was extremely hard for us to get sales representatives, clinical experts out there into the market that’s demonstrating the product. And I would expect that we’ll keep seeing that ramp now as people — more people are getting vaccinated and our access to the hospital will be far better.
Richard Newitter
analystI just had a quick follow-up. I think there might be a bit of uncertainty regarding what was said about UroLift growth rates before COVID. Liam, could you clear that up — I believe you grew more than 30% in April. What is that measured against? Is it against April 2020, or against April 2019?
Liam Kelly
executiveIt was against — so that 30% figure was for March, and the comparison was March of 2020, Rich. The 30% I mentioned applied to the quarter, and that was measured against 2019. So during March we grew 30% versus March of 2020. And for the entire first quarter of 2021, our growth was 30% compared with 2019. When we moved into April, our average daily sales returned to the average daily sales levels that we had not experienced on a consistent basis since January and February of 2020, prior to entering COVID.
Richard Newitter
analystAll right. And from what I understood, January and February of 2020 were unusually robust — I mean, considerably above 30%?
Liam Kelly
executiveThat's right. Based on what I recall, our growth during January and February was roughly 30-ish percent or so, Rich.
Shagun Singh
analystSorry, can you hear me?
Liam Kelly
executiveYes.
Shagun Singh
analystIf we look back at the years before COVID, Q2 sales usually run 6% above Q1, and EPS comes in roughly 60% higher. From what I can tell, your Q2 guidance assumes 5% sequential growth with EPS flat at the midpoint. So I wanted to ask whether you could speak to that for Q2 relative to Q1? Then, when I look at growth on a stacked 3-year basis, it looks fairly similar for Q2 compared with what you're projecting for the back half. Should we take that as conservative? That leads into my last question, which concerns backlog. What's your thinking there? I keep hearing more often that we ought to expect a steadier flow at elevated levels rather than a catch-up, so to speak, spread across a one or two quarter stretch. So any thoughts on that would be useful.
Liam Kelly
executiveYes. I'll begin with backlog and the — I'll take up the conservatism point, and I'll let Tom get into the guide's specifics for the quarter as to where it would land; but what I'd say is that you will see revenue dollars accelerate, and you'll see adjusted earnings per share accelerate as the quarter progresses, I think that's where we should start since we continue to expect the recovery to carry on; forecasting or identifying the backlog is really hard for us, and building it into any forecast is hard for us too, because we don't know what kind of capacity will exist within the hospital system or outside the hospital system for us to get there. Our expectation, though, is that backlog ought to get burned through as you move later into the year, and that's what we'd expect. As for whether the guide — so the guide would be roughly — and I'm trying — aiming this toward the middle here, Shagun, so it should come to about $690 million and roughly $0.02 in earnings per share at the midpoint across both pieces of guidance we provided on that. Now on whether it's conservative or not, I think we keep seeing some rises in COVID cases in places like India and Japan; we see the Americas recovering. We think OEM will keep improving in the second quarter, as EMEA will too. And we do believe there could be opportunities for us there in the second quarter, but at this stage we'd rather lean conservative than be aggressive, simply because a few variants are circulating, so we'd rather lean that way; and if recovery carries on within Q2, we think we should be well positioned to capitalize on that, that would be our thinking. Let me make this completely clear: that figure of $690 million would represent a rise compared with the roughly $634 million we posted during this quarter, Shagun. So on revenue, measured in absolute dollars, you would be looking at meaningful sequential growth.
Thomas Powell
executiveNow, regarding profits, Liam mentioned, I believe, that we anticipate quarter-over-quarter growth in earnings per share. We also anticipate that adjusted earnings per share will improve sequentially compared to the same period last year. If you look back 2 years, I believe we enjoyed a particularly strong Q1, and the growth rate is weaker in the latter half of the year. There are a few points to grasp as we examine Q1 of 2021: I noted previously that, from the perspective of manufacturing performance, our first quarter was quite clean. Although that performance gives us a lot of encouragement, we aren't quite prepared to project that it will provide upside at that level for the entire year. In addition, I noted that EMEA and OEM saw revenue growth decline in Q1, and for the second half of the year, we anticipate they will rebound and move into positive territory. Both of those business segments have a gross margin that is below average. I would also note that during Q1, we experienced a truly substantial beat on operating expenses, some of which came from travel-related savings and possibly slower-than-anticipated hiring. However, deferred projects accounted for the great majority of it. Thus, projects we had anticipated starting in Q1 were ultimately postponed due to COVID and other factors. We do, however, anticipate recovering those in the latter half of the year. Therefore, we anticipate that a portion of that OpEx savings and Q1 upside will be reflected in spending for the remainder of the year. So I hope that clarifies what is happening from a profit perspective and why, when fairly compared to 2 years ago, Q1 appears so incredible.
Dave Turkaly
analystI've been running around quite a bit today, so I'll keep this to one fast question for Tom. You brought up a subject that's gotten plenty of attention lately, generally speaking — inflation. What exactly are you pointing to there? And is there anything on the input side we ought to know about that could be facing a price hike for the remainder of this year?
Thomas Powell
executiveAbsolutely. What I'd tell you is that inflation in 2021 is coming in somewhat above what we've experienced in past years. Much of that was expected and baked into the plan we started with. What we're projecting now captures the conditions as we currently see them. The places where inflation is showing up include certain materials — specifically resin, polyethylene, polypropylene, and polystyrene are each running at inflation rates comfortably beyond 10%. Taken as a whole, though, materials are growing at an inflation rate below 2%. On the labor side, certain markets are seeing pressure — in Malaysia we have inflation that's trending toward roughly 5%. Even so, when you combine direct and indirect labor, inflation sits below 5%. Freight is another category where inflation has picked up. Sea freight especially has climbed a great deal — it's 20% higher this year. If you're tracking the situation, capacity simply isn't there. So when we add up every inflation element across manufacturing, our present estimate puts us at about 3% for the year. That's roughly a full point above what history has shown us. And once more, our current projections already account for all of it.
Liam Kelly
executiveTo add to that point, and I touched on this briefly before, we expected to encounter some of this inflationary pressure. So over roughly the past 12 months, we began putting certain measures in place regarding a number of our pricing programs. That began showing up during this first quarter. On a pure pricing basis, Q1 came in at approximately positive 20 basis points. That leaves us feeling fairly optimistic. We saw this coming, and right away we started working out how to counterbalance it — meaning small price increases in certain more targeted parts of the business.
Jake Elguicze
executiveThanks, operator, and I appreciate all of you for being with us on today's call. That brings the Teleflex Inc. First Quarter 2021 Earnings Conference Call to a close. Enjoy the rest of your day.
Operator
operatorLadies and gentlemen, thank you for participating. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.